Company Obtains U.S. Patent Notice of Allowance for Angiogenic Technology

Haifa, November 23, 2017, Bonus BioGroup (TASE: BONS.TA), an Israeli biotechnology company engaged in tissue engineering and cell therapy, and developing proprietary technology for growing live human bone grafts for implant in human patients, announces today that on November 22, 2017, Bonus Cellora, a corporation controlled by the Company, obtained notice of allowance from the United States Patent and Trademark Office (USPTO) for registering a U.S. patent granting exclusive rights to use proprietary angiogenic technology within the U.S.

 

The process at the base of the proprietary technology occurs through introduction of bioactive material to the implant area, causing specific cells in the patient's body to secrete protein and desirable regeneration agents, encouraging local vascularization of ischemic tissues.
The proprietary technology is based, inter alia, on chemistry, biotechnology and materials science and engineering.


Prior to obtaining notice of allowance from the USPTO for registering the proprietary technology as a U.S. patent, approval was obtained from the European Patent Office (EPO) for registering such technology as an approved European patent. The approved patent grants the Company exclusive use of the technology until November 24, 2029, either separately or in combination with the Company's tissue engineering technology, based on the Company's patents and patent applications.


Save for approved patents at the base of the proprietary angiogenic technology, Bonus BioGroup currently holds exclusive rights in six families of patents, which include ten additional patent applications. The exclusivity period for using technology covered by approved patents commences on the date of filing, at latest, and ends, in most instances, upon the lapse of 20 years.

 

Bonus BioGroup is actively pursuing registration of additional patents and patent applications, to add additional indications for the revolutionary breakthrough demonstrated for safe, rapid and efficient bone rehabilitation, through a single bone graft injection, manufactured by the Company, as successfully demonstrated in all participants of the Company's first clinical trial for repairing maxillofacial bone deficiencies in the upper or lower jaw, regardless of sex, age and medical background, and recorded a significance level of 95%.


Concurrently to conducting the first clinical trial, Bonus BioGroup has developed a second generation of injectable bone graft, which is more advanced, reduces manufacturing time, with less human involving, at a reduced cost and with suitability for mass production.


Currently, Bonus BioGroup is conducting two clinical trials for its injectable bone graft, both defined Phase I/II, with the clinical objectives of evaluating safety and efficacy of using the second generation of injectable bone graft, manufactured by the Company, as follows:
1. In September 2016, a second clinical trial began for filling bone void in the upper or lower jawbone;
2. In August 2017, a clinical trial began for filling critical bone voids in limbs – arms or legs.